Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational... see more

NDAQ:PMN - Post Discussion

ProMIS Neurosciences Inc > U.S. lawmakers to investigate approval, pricing of Alzheimer
View:
Comment by Gbathat on Jun 25, 2021 9:12pm
Here's what I took away from that article... holy smokes... if true, biib still undervalued... I've been using $25B for the global market, so $57B just for the medicare market is insanity "At $56,000 a year, the Kaiser Family Foundation estimates that Medicare could spend $57 billion or more per year on Aduhelm, which is more than Medicare Part B spends on all other drugs combined ...more  
Comment by retiredcop on Jun 26, 2021 7:50am
So we move into a potential opportunity where PMN310 could prove that they have a drug that works better then Aduhelm and has addressed the concerning side effects Aduhelm has...but even more desirable with this recent controversy,  a drug that will cost much less then the Aduhelm .  I go back to a few years ago when PMN first revealed their completed PMN310.... for some reason I ...more  
Comment by DavidKingCanada on Jun 26, 2021 9:53am
Great analysis!
Comment by G1945V on Jun 26, 2021 12:32pm
Drug Profile for PMN310 https://adisinsight.springer.com/drugs/800056328 ________________________________________________________________________ "PMN 310 Alternative Names: huPMN-310; PMN-310 Latest Information Update: 23 Oct 2019 Price : $50 *   Adis is an information provider. We do not sell or distribute actual drugs. Final gross price and currency may ...more  
Comment by Speyeder999 on Jun 27, 2021 5:05am
Very interesting (lol) Did a search to see where we stand with our competition.... What is the track record for predictions for these guys? A Phase 1 Placebo-Controlled, Single- and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous ACU193 in Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease Status: Not Yet ...more  
Comment by Speyeder999 on Jun 27, 2021 7:35am
....then again....I checked for aducanumab and it to is priced at 50$....or any other drug for that matter, so not sure what this signifies.
Comment by retiredcop on Jun 27, 2021 12:10pm
https://news.google.com/articles/CAIiENKfG-zYzToITeJiUdojfaUqEwgEKgwIACoFCAowgHkwoBEwwjU?hl=en-CA&gl=CA&ceid=CA%3Aen
Comment by retiredcop on Jul 02, 2021 7:01am
https://www.fiercepharma.com/pharma/biogen-s-56k-price-tag-for-alzheimer-s-drug-aduhelm-worth-it-watchdog-says-try-more-like-8
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities